Position in EXEL
as of Mar 31, 2026
· filed Apr 29, 2026
Position Value
$11,580
+$10,572 QoQ
Shares Held
270
+1073.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CVA Family Office, LLC holds $673,464 across 40 Biotechnology names. EXEL ranks #7 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
472 | $210,766 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
194 | $149,892 | |
| 3 | MRNA |
Moderna, Inc.
|
1,701 | $86,410 | |
| 4 | INCY |
Incyte Corp
|
904 | $85,084 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
92 | $30,440 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
84 | $15,880 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
270 | $11,580 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
146 | $10,841 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,580 | 270 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $1,008 | 23 | Shares | Sole | 2026-01-12 | |
| 2025-09-30 | $949 | 23 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $1,013 | 23 | Shares | Sole | 2025-07-31 | |
| 2025-03-31 | $849 | 23 | Shares | Sole | 2025-04-16 | |
| 2024-12-31 | $765 | 23 | Shares | Sole | 2025-01-07 | |
| 2024-09-30 | $596 | 23 | Shares | Sole | 2024-10-10 | |
| 2024-06-30 | $516 | 23 | Shares | Sole | 2024-07-10 | |
| No filing history on record for this holder in this stock. | ||||||